---
title: "Vraylar (cariprazine), all indications: Safety questions"
description: "Safety questions on Vraylar (cariprazine) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Monitoring. Questions: Does Vraylar prolong the QT interval? What is the Vraylar boxed warning about dementia and suicidal thoughts? What are the contraindications for Vraylar? What are the warnings and precautions for Vraylar? 4 further questions follow. 8 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/vraylar/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vraylar (cariprazine), all indications: Safety questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Vraylar](https://www.rxabbvie.com/pdf/vraylar_pi.pdf)  
Indication pages: [Major depressive disorder](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder)

## Safety

<a id="vraylar-qt-prolongation"></a>

### Does Vraylar prolong the QT interval?

> “At a dose three times the maximum recommended dose, cariprazine does not prolong the QTc interval to 
> clinically relevant extent.”

Source: [VRAYLAR: Prescribing information, page 31, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=31)

<a id="vraylar-controlled-substance"></a>

### Is Vraylar a controlled substance?

> “VRAYLAR is not a controlled substance. 
>
> 9.2 
> Abuse  
> VRAYLAR has not been systematically studied in animals or humans for its abuse potential or its ability 
> to induce tolerance.   
>
> 9.3 
> Dependence 
> VRAYLAR has not been systematically studied in animals or humans for its potential for physical 
> dependence.”

Source: [VRAYLAR: Prescribing information, page 30, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=30)

<a id="vraylar-overdose"></a>

### What happens after a Vraylar overdose?

> “In pre-marketing clinical trials involving VRAYLAR in approximately 5000 patients or healthy subjects, 
> accidental acute overdosage (48 mg/day) was reported in one patient. This patient experienced 
> orthostasis and sedation. The patient fully recovered the same day. 
>
> 10.2 
> Management of Overdosage  
> No specific antidotes for VRAYLAR are known. In managing overdose, provide supportive care, 
> including close medical supervision and monitoring, and consider the possibility of multiple drug 
> involvement. In case of an overdose, consult a Certified Poison Control Center (1-800-222-1222) for up-
> to-date guidance and advice.”

Source: [VRAYLAR: Prescribing information, page 30, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=30)

## Warnings

<a id="vraylar-boxed-warning"></a>

### What is the Vraylar boxed warning about dementia and suicidal thoughts?

> “WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-
> RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS 
>
> Increased Mortality in Elderly Patients with Dementia-Related Psychosis 
> Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an 
> increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-
> related psychosis [see Warnings and Precautions (5.1)]. 
>
> Suicidal Thoughts and Behaviors 
> Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young 
> adult patients in short-term studies. Closely monitor all antidepressant-treated patients for 
> clinical worsening, and for the emergence of suicidal thoughts and behaviors [see Warnings and 
> Precautions (5.2)].”

Source: [VRAYLAR: Prescribing information, page 3, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=3)

<a id="vraylar-contraindications"></a>

### What are the contraindications for Vraylar?

> “VRAYLAR is contraindicated in patients with history of a hypersensitivity reaction to cariprazine. 
> Reactions have ranged from rash, pruritus, urticaria, and reactions suggestive of angioedema (e.g., 
> swollen tongue, lip swelling, face edema, pharyngeal edema, and swelling face).”

Source: [VRAYLAR: Prescribing information, page 6, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=6)

<a id="vraylar-warnings"></a>

### What are the warnings and precautions for Vraylar?

> “Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-
> Related Psychosis: Increased incidence of cerebrovascular adverse 
> reactions (e.g., stroke, transient ischemic attack) (5.3) 
> • 
> Neuroleptic Malignant Syndrome: Manage with immediate 
> discontinuation and close monitoring (5.4) 
> • Tardive Dyskinesia: Discontinue if appropriate (5.5) 
> • 
> Late-Occurring Adverse Reactions: Because of VRAYLAR’s long half-
> life, monitor for adverse reactions and patient response for several 
> weeks after starting VRAYLAR and with each dosage change (5.6) 
> • Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, 
> dyslipidemia and weight gain (5.7) 
> • 
> Leukopenia, Neutropenia, and Agranulocytosis: Perform complete 
> blood counts (CBC) in patients with pre-existing low white blood cell 
> counts (WBC) or history of leukopenia or neutropenia. Consider 
> discontinuing VRAYLAR if a clinically significant decline in WBC 
> occurs in absence of other causative factors (5.8) 
> • Orthostatic Hypotension and Syncope: Monitor heart rate and blood 
> pressure and warn patients with known cardiovascular or 
> cerebrovascular disease, and risk of dehydration or syncope (5.9) 
> • Seizures: Use cautiously in patients with a history of seizures or with 
> conditions that lower the seizure threshold (5.11) 
> • Potential for Cognitive and Motor Impairment: Use caution when 
> operating machinery (5.12)”

Source: [VRAYLAR: Prescribing information, page 1, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=1)

<a id="vraylar-late-occurring-side-effects"></a>

### Why can Vraylar side effects start weeks after treatment begins?

> “Late-Occurring Adverse Reactions: Adverse reactions may first appear several weeks after initiation of VRAYLAR, probably because plasma levels of cariprazine and its major metabolites accumulate over time. As a result, the incidence of adverse reactions in short-term trials may not reflect the rates after longer-term exposures. Monitor for adverse reactions, including extrapyramidal symptoms (EPS) or akathisia, and patient response for several weeks after starting VRAYLAR and after each dosage increase. Consider reducing the dose or discontinuing the drug.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=Late%2DOccurring%20Adverse%20Reactions%3A%20Adverse%20reactions,dose%20or%20discontinuing%20the%20drug.)

## Monitoring

<a id="vraylar-monitoring"></a>

### What monitoring does Vraylar require?

> “Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics. Assess fasting glucose before or soon after initiation of treatment, and monitor periodically during long-term treatment.
> Dyslipidemia: Atypical antipsychotics cause adverse alterations in lipids. Before or soon after starting an antipsychotic, obtain baseline fasting lipid profile and monitor periodically during treatment.
> Weight Gain: Weight gain has been observed with VRAYLAR. Monitor weight at baseline and frequently thereafter.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=Hyperglycemia%20and%20Diabetes%20Mellitus%3A%20Hyperglycemia%2C,at%20baseline%20and%20frequently%20thereafter.)

> “Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue VRAYLAR at the first sign of a clinically significant decline in WBC and in severely neutropenic patients.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=Monitor%20complete%20blood%20count%20in,and%20in%20severely%20neutropenic%20patients.)

> “Monitor orthostatic vital signs in patients predisposed to hypotension and in those with cardiovascular/cerebrovascular diseases.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=Monitor%20orthostatic%20vital%20signs%20in,in%20those%20with%20cardiovascular%2Fcerebrovascular%20diseases.)

## Related pages
- [Medical information: Vraylar (cariprazine): All indications](https://www.evicenter.com/medical-information/vraylar)
- [Indication](https://www.evicenter.com/medical-information/vraylar/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vraylar/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/vraylar/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vraylar/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vraylar/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vraylar/storage-and-supply)
